The Hawk Stocks

Still new here on X.
Ex-hedge fund | Hunting 5–10x growth plays | Tech, AI, Biotech | NFA

[The Hawk Stocks @TheHawkStocks]

I’m putting $BCRX on the table.

Not because of the rumors.
Because the market is completely asleep on what this company actually is.

I took a starter of 50,000 Shares

Here’s why 🧵

[The Hawk Stocks @TheHawkStocks]

@QC_Capitals My experience says ETFs AND stocks

[The Hawk Stocks @TheHawkStocks]

I guess what he’s trying to say is Abivax is now in the best position to be bought or continue alone and double the share price within the next year with the current pipeline

With the huge demand of big pharma for more future revenues, he is currently the CEO with best power in the industry

[The Hawk Stocks @TheHawkStocks]

@Mr_Derivatives I think the market is already pricing the instability in the Middle East

I also think that what’s happening in the market is actually more bullish in the long-term

Either way we can correct 3 to 5% from here, but I’m confident the market will buy this dip

[The Hawk Stocks @TheHawkStocks]

@smithy05261244 @5pacely5procket I tried to DM you

[The Hawk Stocks @TheHawkStocks]

$ABVX

That secondary printing 8X oversubscribed isn’t random. Smart money doesn’t pile in like that on a standalone story.

Zero job openings last check. Companies don’t freeze hiring when they’re playing GIA.

Marc isn’t rushing to sign anything. He looked calm on CNBC, almost too calm. My read: he’s sitting back because there’s more than one bidder at the table.

With the patent cliff bearing down on big pharma this decade, everyone needs pipeline. This isn’t a quiet process. It’s a bidding war, and Marc knows it

[The Hawk Stocks @TheHawkStocks]

Took 2,000 shares of solana:SKHYhSjuRWHgikq8eRKbtBbpABgJSkd7ytQV14i9EQ3 at 171$~

I’m confident it’s going to 200$ in the short term and if we’ll get a dip below 160$ I’ll buy another 2,000 every 5$

ETF managers will start buying soon, funds and retail will eat every available share.

$SOXX $MU $SMH

[The Hawk Stocks @TheHawkStocks]

$ABVX “The M&A Opportunities are massive”

https://t.co/qftEEnQ83C

[The Hawk Stocks @TheHawkStocks]

$ABVX this is going to 230$ if u like it or not

Everything that could be bearish, is now the past

1. The offering was OVERSUBSCRIBED 4-5 times
2. Cancer cases were Nonesense
3. Company has a massive pipeline and if they run by themselves what they currently have is already worth around 165-170$
4. In an article, they have confirmed that they are in talks with a few few big pharmas

Don’t miss it. Just chill. Let them work.

$XBI $ABVX

[The Hawk Stocks @TheHawkStocks]

I noticed $BCRX employees from the closed lab in Alabama already have started to look for work on LinkedIn.

The way the stock is trading is interesting..

[The Hawk Stocks @TheHawkStocks]

@MartinShkreli $BCRX can save them

[The Hawk Stocks @TheHawkStocks]

@unusual_whales Think about it for a sec. This guy controls the super intelligence of war.

He knows more than all of us.
If he’s for them, there might be a reason

[The Hawk Stocks @TheHawkStocks]

$BCRX 3X upside, backed by Shkreli?

I’ll take that

$XBI $ABVX

[Martin Shkreli @MartinShkreli]

long idea: $BCRX trading at steep discount to sum of its two parts - $10 stock should trade for $30 - HAE king in the making with navenibart

[The Hawk Stocks @TheHawkStocks]

Back in March there was chatter about a Battleville-related rumor on $BCRX. At the time it felt premature. It isn’t anymore.

Since then: discovery ops shut down, an external-innovation-only model, board seats filled with people who’ve sold companies before, debt structure getting cleaner. Every single move points the same direction. I’ve watched this exact sequence play out enough times on Wall Street to know what it usually means.

[The Hawk Stocks @TheHawkStocks]

@MartinShkreli What about $BCRX ? Bulls need your call

[The Hawk Stocks @TheHawkStocks]

Same day they close the lab, they cut $30M off opex guidance AND reaffirm full revenue guidance.

That’s not a restructuring. That’s a company removing every deal blocker on a buyer’s checklist.

Clean commercial asset. Phase 3 complete. Costs cut. Revenue intact.

Stock at $9. Analysts at $30

$BCRX

[The Hawk Stocks @TheHawkStocks]

“BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility”

Here is why this is ultra bullish and an acquisition might come very soon.
$BCRX

[The Hawk Stocks @TheHawkStocks]

Phase 3 ALPHA-ORBIT enrollment is complete.

Navenibart is on track to be the FIRST HAE therapy ever with both 3 and 6-month dosing evaluated through 12 months.

Data readout Q3 2027.

The window between enrollment close and data is THE prime acquisition window. Every major rare disease deal gets done right here.
$BCRX

[The Hawk Stocks @TheHawkStocks]

Different patients. Different profiles. Some don’t want pills daily. Some can’t tolerate oral. That’s exactly why you need both

the pill AND the long-acting injectable.

Monopoly on the oral side. Best-in-class on the injectable side. One company owns both lanes.

Tell me again why that’s cheap for good reason.

[The Hawk Stocks @TheHawkStocks]

I’m putting $BCRX on the table.

Not because of the rumors.
Because the market is completely asleep on what this company actually is.

I took a starter of 50,000 Shares

Here’s why 🧵

[The Hawk Stocks @TheHawkStocks]

@MartinShkreli 100% my friend